Would an hCG test using a monoclonal antibody against the β-subunit of hCG likely be affected by an increased level of follicle-stimulating hormone (FSH)?

The answer indicates that the hCG test using a monoclonal antibody against the β-subunit of hCG would not be affected by an increased level of follicle-stimulating hormone (FSH) because the test is designed to specifically target the β-subunit of hCG. Monoclonal antibodies are engineered to recognize and bind to specific antigens with high specificity. In this case, the β-subunit of hCG is distinct from that of FSH.

FSH and hCG each have unique structures that allow for the specificity of the test. While FSH and hCG both belong to the glycoprotein hormone family and share some common features, the specific monoclonal antibody used in the test would selectively bind only to the unique β-subunit of hCG, which means that increased levels of FSH would not interfere with the accuracy of the hCG test.

The specificity of the antibody is crucial in assays to prevent cross-reactivity, which could lead to false-positive results. Therefore, the design of this particular test ensures that it accurately measures the hCG levels without the influence of FSH.